Gelesis Holdings, Inc. (GLSHQ)

Market Cap	73.00
Revenue (ttm)	12.14M
Net Income (ttm)	-51.67M
Shares Out	73.34M
EPS (ttm)	-0.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	125
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	0.0000 - 0.0530
Beta	3,512.73
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Gelesis Holdings

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporate...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 93
• Stock Exchange: OTCMKTS
• Ticker Symbol: GLSHQ

Financial Performance

In 2022, Gelesis Holdings's revenue was $25.77 million, an increase of 130.37% compared to the previous year's $11.19 million. Losses were -$95.06 million, -49.40% less than in 2021.